PL420113A1 - (Quinoline or isoquinoline) cyclic amine sulfonamides as antipsychotics - Google Patents
(Quinoline or isoquinoline) cyclic amine sulfonamides as antipsychoticsInfo
- Publication number
- PL420113A1 PL420113A1 PL420113A PL42011314A PL420113A1 PL 420113 A1 PL420113 A1 PL 420113A1 PL 420113 A PL420113 A PL 420113A PL 42011314 A PL42011314 A PL 42011314A PL 420113 A1 PL420113 A1 PL 420113A1
- Authority
- PL
- Poland
- Prior art keywords
- ring
- nitrogen
- aromatic
- antipsychotics
- isoquinoline
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 2
- 239000000164 antipsychotic agent Substances 0.000 title 1
- 229940005529 antipsychotics Drugs 0.000 title 1
- -1 cyclic amine sulfonamides Chemical class 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 108091005436 5-HT7 receptors Proteins 0.000 abstract 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 1
- 102100040368 5-hydroxytryptamine receptor 6 Human genes 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 101150015707 HTR1A gene Proteins 0.000 abstract 1
- 101150104779 HTR2A gene Proteins 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000506 psychotropic effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000000862 serotonergic effect Effects 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Zgłoszenie dotyczy związków o wzorze ogólnym (I), w którym: jeden z A1 i A2 oznacza atom azotu, a drugi oznacza atom węgla ewentualnie podstawiony halogenem; linia falista pomiędzy ugrupowaniem sulfonamidowym a pierścieniami B/C oznacza wiązanie pojedyncze łączące atom siarki z nie-przyczółkowym atomem węgla, przy czym część pierścienia C odznaczona linią przerywaną jest niepodstawiona; n oznacza liczbę całkowitą od 0 do 3; Y oznacza atom azotu lub atom węgla; Z oznacza 5-6 członowy pierścień aromatyczny/heteroaromatyczny, ewentualnie skondensowany z dalszym pierścieniem aromatycznym lub 5-6 członowym nie-aromatycznym pierścieniem heterocyklicznym, przy czym skondensowany układ pierścieni jest połączony przez nie-przyczółkowy atom węgla. Związki wykazują wysokie powinowactwo do receptorów D2, D3, 5-HT1A, 5-HT2A, 5-HT6 i 5-HT7 i są użyteczne w leczeniu chorób psychotropowych lub zaburzeń związanych z dysfunkcją układów dopaminergicznego/serotoninergicznego, takich jak schizofrenia i autyzm.The application relates to compounds of the general formula (I) in which: one of A1 and A2 is nitrogen and the other is carbon optionally substituted with halogen; the wavy line between the sulfonamide moiety and the B / C rings is a single bond connecting a sulfur atom to a non-bridgehead carbon atom, the portion of the C ring marked with a dashed line is unsubstituted; n is an integer from 0 to 3; Y is nitrogen or carbon; Z is a 5-6 membered aromatic / heteroaromatic ring, optionally fused to a distal aromatic ring or a 5-6 membered non-aromatic heterocyclic ring, the fused ring system being connected by a non-bridgehead carbon atom. The compounds exhibit high affinity for D2, D3, 5-HT1A, 5-HT2A, 5-HT6 and 5-HT7 receptors and are useful in the treatment of psychotropic diseases or disorders associated with dopaminergic / serotonergic dysfunction such as schizophrenia and autism.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/PL2014/000072 WO2016003296A1 (en) | 2014-07-04 | 2014-07-04 | (quinoline or isoquinoline)sulfonamides of cyclic amines as antipsychotic drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL420113A1 true PL420113A1 (en) | 2017-10-23 |
| PL245933B1 PL245933B1 (en) | 2024-11-04 |
Family
ID=51230155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL420113A PL245933B1 (en) | 2014-07-04 | 2014-07-04 | (Quino or isoquinoline) cyclic amine sulfonamides, compositions containing them, methods for their preparation and medical use thereof |
Country Status (2)
| Country | Link |
|---|---|
| PL (1) | PL245933B1 (en) |
| WO (1) | WO2016003296A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104892589A (en) * | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | Heterocyclic compound, preparation method therefor and use thereof |
| US20220268517A1 (en) * | 2019-08-13 | 2022-08-25 | Bechtel Energy Inc. | Systems and Methods for Improving the Efficiency of Open-Cycle Cascade-Based Liquified Natural Gas Systems |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9612884D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| US20040267010A1 (en) | 2001-02-02 | 2004-12-30 | Forbes Ian Thomson | Sulfonamide compounds, their preparation and use |
| AU2011225095C1 (en) | 2010-03-11 | 2017-01-19 | Sumitomo Dainippon Pharma Co., Ltd. | N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof |
-
2014
- 2014-07-04 WO PCT/PL2014/000072 patent/WO2016003296A1/en not_active Ceased
- 2014-07-04 PL PL420113A patent/PL245933B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL245933B1 (en) | 2024-11-04 |
| WO2016003296A1 (en) | 2016-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551065A1 (en) | Fused ring compounds | |
| MX2020000261A (en) | NEW COMPOUNDS. | |
| EA202092896A1 (en) | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE | |
| PH12019500712A1 (en) | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | |
| MX2021013075A (en) | OXYSTEROLS AND METHODS OF USE THEREOF. | |
| AR102306A1 (en) | USEFUL NEUROACTIVE STEROIDS IN THE TREATMENT OF CNS DISEASES | |
| PE20190711A1 (en) | N- (ULFONIL FENILS) BENZAMIDS AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | |
| EA202190196A1 (en) | NEW HETEROCYCLIC DERIVATIVES USED AS SHP2 INHIBITORS | |
| MX390698B (en) | TOLL-TYPE 7/8 RECEPTOR ANTAGONISTS (TLR7/8) AND THEIR USE. | |
| SG11201900869QA (en) | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | |
| MX2016014197A (en) | 4-PHENYLPIPERIDINS REPLACED, ITS PREPARATION AND USE. | |
| CR20150412A (en) | THYZOLCARBOXAMIDES AND PYRIDINACARBOXAMIDE COMPOUNDS USEFUL AS INHIBITORS OF QUINASA PIM | |
| BR112017009648A2 (en) | compound, methods for treating allergic diseases or other inflammatory conditions or preventing disease, allergic rhinitis or asthma, composition, and use of a compound. | |
| AR099400A1 (en) | FUSED HETEROCYCLIC COMPOUND | |
| MX379579B (en) | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF THEIR USE. | |
| MX369956B (en) | Methods of manufacturing benzoquinoline compounds. | |
| MX392270B (en) | C7-SUBSTITUTED OXYSTEROLS AND METHODS OF USING THEM. | |
| JO3811B1 (en) | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors | |
| BR112017009595A2 (en) | morpholine and 1,4-oxazepane amides as agonists of the somatostatin 4 receptor subtype (sstr4) | |
| MX2021000093A (en) | Tlr7/8 antagonists and uses thereof. | |
| MX2017013678A (en) | 6-membered heterocyclic derivative and pharmaceutical composition comprising same. | |
| AR118784A1 (en) | AMIDE COMPOUND WHICH HAS ACTION INDUCING BET PROTEIN DEGRADATION AND ITS USE AS A MEDICINE | |
| BR112015017740A2 (en) | condensed heterocyclic compound | |
| MD4865B1 (en) | Use of trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine for treating primary negative symptoms of schizophrenia | |
| AR110240A1 (en) | DIAMINOTRIAZINE COMPOUNDS |